|
||||||||||||||||||
|
||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionThe MIH1 monoclonal antibody reacts with human B7-H1, also known as PD-L1. B7-H1, a member of the B7 family, has a predicted molecular weight of approximately 40 kDa and belongs to the Ig superfamily. B7-H1 is expressed on a majority of leukocytes. B7-H1 is a ligand for PD-1. Interaction of PD-1 with either PD-L1 (B7-H1) or PD-L2 (B7-DC) results in inhibition of T and B cell responses. MIH1 is reported to be a blocking antibody. Applications ReportedFor research use only, not for diagnostic or therapeutic use. The MIH1 antibody has been reported for use in flow cytometric analysis, and immunohistochemical staining of frozen tissue sections. It has also been reported in blocking in in vitro functional assays. (Please use Functional Grade purified MIH1, cat. 16-5983, in functional assays.) Applications TestedThe MIH1 antibody has been tested by flow cytometric analysis of human peripheral leukocytes. This can be used at less than or equal to 1 μg per million cells in a 100 μl total staining volume. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. References
Dong, H., G. Zhu, et al. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5(12): 1365-9. Freeman, G. J., A. J. Long, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7): 1027-34. Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, Fukushima T, Akiba H, Yagita H, Okumura K, Machida U, Iwai H, Azuma M, Chen L, Watanabe M. 2003. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol. 171(8):4156-63. Saudemont, A., Jouy, N., Hetuin, D., and Quesnel, B. 2005. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood. 105:2428-2435. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005 Apr 15;11(8):2947-53. (MIH1, IH/F, PubMed) Chen Y, Zhang J, Li J, Zou L, Zhao T, Tang Y, Wu Y. Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp Nephrol. 2006;102(3-4):e81-92. (MIH1, IH/F, FA, PubMed) Related ProductsCat. 11-4011 FITC Anti-Mouse IgG Cat. 13-4013 Biotin Anti-Mouse IgG (clone Polyclonal) Cat. 11-4317 Streptavidin-FITC (Fluorescein isothiocyanate) Cat. 12-4317 Streptavidin-PE (Phycoerythrin) Cat. 17-4317 Streptavidin Allophycocyanin (SA-APC) Cat. 14-4714 Affinity Purified Mouse IgG1, K Isotype Control |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |